ACSS2 and metabolic diseases: from lipid metabolism to therapeutic target
Abstract Elevated incidence of metabolic disorders has been reported worldwide in the recent decade, highlighting the need for developing efficient therapies. These diseases result from a complex interplay of various factors that contribute to disease progression, complications, and resistance to cu...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-02-01
|
| Series: | Lipids in Health and Disease |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12944-025-02491-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850238092677480448 |
|---|---|
| author | Alaa El-Kurjieh Reem Al-Arab Qamar Abou Hachem José-Noel Ibrahim Philippe Hussein Kobeissy |
| author_facet | Alaa El-Kurjieh Reem Al-Arab Qamar Abou Hachem José-Noel Ibrahim Philippe Hussein Kobeissy |
| author_sort | Alaa El-Kurjieh |
| collection | DOAJ |
| description | Abstract Elevated incidence of metabolic disorders has been reported worldwide in the recent decade, highlighting the need for developing efficient therapies. These diseases result from a complex interplay of various factors that contribute to disease progression, complications, and resistance to current treatment options. Acetyl-CoA Synthetase Short Chain Family Member 2 (ACSS2) is a nucleo-cytosolic enzyme with both lipogenic and metabolic regulatory roles. Studies on ACSS2 have shown that it is involved in pathways commonly dysregulated in metabolic disorders, leading to fat deposition and disrupted cellular signaling. Although multiple studies have suggested a role of ACSS2 in the metabolic rewiring during tumorigenesis, few studies have examined its involvement in the pathophysiology of metabolic diseases. Recent evidence indicates that ACSS2 may contribute to the pathogenesis of various metabolic disorders making its examination of great interest and potentially aiding in the development of new therapeutic strategies. The objective of this review is to summarize the current understanding of ACSS2’s role in metabolic disorders and its potential as a therapeutic target. |
| format | Article |
| id | doaj-art-7ef64450571a418b9a08df9dbb6e772d |
| institution | OA Journals |
| issn | 1476-511X |
| language | English |
| publishDate | 2025-02-01 |
| publisher | BMC |
| record_format | Article |
| series | Lipids in Health and Disease |
| spelling | doaj-art-7ef64450571a418b9a08df9dbb6e772d2025-08-20T02:01:34ZengBMCLipids in Health and Disease1476-511X2025-02-0124111710.1186/s12944-025-02491-zACSS2 and metabolic diseases: from lipid metabolism to therapeutic targetAlaa El-Kurjieh0Reem Al-Arab1Qamar Abou Hachem2José-Noel Ibrahim3Philippe Hussein Kobeissy4Department of Biological Sciences, School of Arts and Sciences, Lebanese American University (LAU)Department of Biological Sciences, School of Arts and Sciences, Lebanese American University (LAU)Department of Biological Sciences, School of Arts and Sciences, Lebanese American University (LAU)Department of Biological Sciences, School of Arts and Sciences, Lebanese American University (LAU)Department of Biological Sciences, School of Arts and Sciences, Lebanese American University (LAU)Abstract Elevated incidence of metabolic disorders has been reported worldwide in the recent decade, highlighting the need for developing efficient therapies. These diseases result from a complex interplay of various factors that contribute to disease progression, complications, and resistance to current treatment options. Acetyl-CoA Synthetase Short Chain Family Member 2 (ACSS2) is a nucleo-cytosolic enzyme with both lipogenic and metabolic regulatory roles. Studies on ACSS2 have shown that it is involved in pathways commonly dysregulated in metabolic disorders, leading to fat deposition and disrupted cellular signaling. Although multiple studies have suggested a role of ACSS2 in the metabolic rewiring during tumorigenesis, few studies have examined its involvement in the pathophysiology of metabolic diseases. Recent evidence indicates that ACSS2 may contribute to the pathogenesis of various metabolic disorders making its examination of great interest and potentially aiding in the development of new therapeutic strategies. The objective of this review is to summarize the current understanding of ACSS2’s role in metabolic disorders and its potential as a therapeutic target.https://doi.org/10.1186/s12944-025-02491-zACSS2De novo lipogenesisDiabetesObesityKidney injuryLiver diseases |
| spellingShingle | Alaa El-Kurjieh Reem Al-Arab Qamar Abou Hachem José-Noel Ibrahim Philippe Hussein Kobeissy ACSS2 and metabolic diseases: from lipid metabolism to therapeutic target Lipids in Health and Disease ACSS2 De novo lipogenesis Diabetes Obesity Kidney injury Liver diseases |
| title | ACSS2 and metabolic diseases: from lipid metabolism to therapeutic target |
| title_full | ACSS2 and metabolic diseases: from lipid metabolism to therapeutic target |
| title_fullStr | ACSS2 and metabolic diseases: from lipid metabolism to therapeutic target |
| title_full_unstemmed | ACSS2 and metabolic diseases: from lipid metabolism to therapeutic target |
| title_short | ACSS2 and metabolic diseases: from lipid metabolism to therapeutic target |
| title_sort | acss2 and metabolic diseases from lipid metabolism to therapeutic target |
| topic | ACSS2 De novo lipogenesis Diabetes Obesity Kidney injury Liver diseases |
| url | https://doi.org/10.1186/s12944-025-02491-z |
| work_keys_str_mv | AT alaaelkurjieh acss2andmetabolicdiseasesfromlipidmetabolismtotherapeutictarget AT reemalarab acss2andmetabolicdiseasesfromlipidmetabolismtotherapeutictarget AT qamarabouhachem acss2andmetabolicdiseasesfromlipidmetabolismtotherapeutictarget AT josenoelibrahim acss2andmetabolicdiseasesfromlipidmetabolismtotherapeutictarget AT philippehusseinkobeissy acss2andmetabolicdiseasesfromlipidmetabolismtotherapeutictarget |